vs
HCI Group, Inc.（HCI）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
HCI Group, Inc.的季度营收约是REPLIGEN CORP的1.2倍（$246.2M vs $197.9M），HCI Group, Inc.净利率更高（39.7% vs 6.7%，领先32.9%），HCI Group, Inc.同比增速更快（52.1% vs 13.6%），HCI Group, Inc.自由现金流更多（$440.8M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 9.2%）
HCI集团是一家总部位于美国华盛顿特区的私募股权投资公司，在伊利诺伊州芝加哥设有分支机构，专注于股权投资相关业务，为合作企业提供资本支持与运营赋能，助力企业实现长期发展目标。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
HCI vs RGEN — 直观对比
营收规模更大
HCI
是对方的1.2倍
$197.9M
营收增速更快
HCI
高出38.5%
13.6%
净利率更高
HCI
高出32.9%
6.7%
自由现金流更多
HCI
多$423.3M
$17.6M
两年增速更快
RGEN
近两年复合增速
9.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $246.2M | $197.9M |
| 净利润 | $97.7M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 58.5% | 9.0% |
| 净利率 | 39.7% | 6.7% |
| 营收同比 | 52.1% | 13.6% |
| 净利润同比 | 3679.2% | 143.9% |
| 每股收益（稀释后） | $7.29 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCIRGEN
| Q4 25 | $246.2M | $197.9M | ||
| Q3 25 | $216.3M | $188.8M | ||
| Q2 25 | $221.9M | $182.4M | ||
| Q1 25 | $216.4M | $169.2M | ||
| Q4 24 | $161.9M | $174.1M | ||
| Q3 24 | $175.3M | $154.9M | ||
| Q2 24 | $206.2M | $154.1M | ||
| Q1 24 | $206.6M | $151.3M |
净利润HCIRGEN
| Q4 25 | $97.7M | $13.3M | ||
| Q3 25 | $65.5M | $14.9M | ||
| Q2 25 | $66.2M | $14.9M | ||
| Q1 25 | $69.7M | $5.8M | ||
| Q4 24 | $2.6M | $-30.3M | ||
| Q3 24 | $5.7M | $-654.0K | ||
| Q2 24 | $54.1M | $3.3M | ||
| Q1 24 | $47.6M | $2.1M |
毛利率HCIRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率HCIRGEN
| Q4 25 | 58.5% | 9.0% | ||
| Q3 25 | 41.9% | 8.9% | ||
| Q2 25 | 42.5% | 7.6% | ||
| Q1 25 | 46.4% | 3.9% | ||
| Q4 24 | 3.6% | -17.7% | ||
| Q3 24 | 8.0% | -5.1% | ||
| Q2 24 | 36.9% | 1.0% | ||
| Q1 24 | 37.5% | 1.3% |
净利率HCIRGEN
| Q4 25 | 39.7% | 6.7% | ||
| Q3 25 | 30.3% | 7.9% | ||
| Q2 25 | 29.8% | 8.2% | ||
| Q1 25 | 32.2% | 3.4% | ||
| Q4 24 | 1.6% | -17.4% | ||
| Q3 24 | 3.2% | -0.4% | ||
| Q2 24 | 26.2% | 2.2% | ||
| Q1 24 | 23.0% | 1.4% |
每股收益（稀释后）HCIRGEN
| Q4 25 | $7.29 | $0.24 | ||
| Q3 25 | $4.90 | $0.26 | ||
| Q2 25 | $5.18 | $0.26 | ||
| Q1 25 | $5.35 | $0.10 | ||
| Q4 24 | $0.32 | $-0.55 | ||
| Q3 24 | $0.52 | $-0.01 | ||
| Q2 24 | $4.24 | $0.06 | ||
| Q1 24 | $3.81 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $1.0B | $2.1B |
| 总资产 | $2.5B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资HCIRGEN
| Q4 25 | $1.2B | $767.6M | ||
| Q3 25 | $987.9M | $748.7M | ||
| Q2 25 | $947.2M | $708.9M | ||
| Q1 25 | $754.5M | $697.2M | ||
| Q4 24 | $532.5M | $757.4M | ||
| Q3 24 | $518.8M | $784.0M | ||
| Q2 24 | $445.8M | $809.1M | ||
| Q1 24 | $655.4M | $780.6M |
总债务HCIRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HCIRGEN
| Q4 25 | $1.0B | $2.1B | ||
| Q3 25 | $821.8M | $2.1B | ||
| Q2 25 | $758.6M | $2.1B | ||
| Q1 25 | $522.7M | $2.0B | ||
| Q4 24 | $453.3M | $2.0B | ||
| Q3 24 | $455.3M | $2.0B | ||
| Q2 24 | $447.3M | $2.0B | ||
| Q1 24 | $395.7M | $2.0B |
总资产HCIRGEN
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | $2.3B | $2.9B | ||
| Q2 25 | $2.4B | $2.9B | ||
| Q1 25 | $2.3B | $2.9B | ||
| Q4 24 | $2.2B | $2.8B | ||
| Q3 24 | $2.0B | $2.8B | ||
| Q2 24 | $1.9B | $2.9B | ||
| Q1 24 | $1.8B | $2.8B |
负债/权益比HCIRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $444.4M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $440.8M | $17.6M |
| 自由现金流率自由现金流/营收 | 179.0% | 8.9% |
| 资本支出强度资本支出/营收 | 1.5% | 4.1% |
| 现金转化率经营现金流/净利润 | 4.55× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $771.4M | $93.9M |
8季度趋势，按日历期对齐
经营现金流HCIRGEN
| Q4 25 | $444.4M | $25.7M | ||
| Q3 25 | $26.7M | $48.1M | ||
| Q2 25 | $145.0M | $28.6M | ||
| Q1 25 | $162.0M | $15.0M | ||
| Q4 24 | $331.8M | $39.2M | ||
| Q3 24 | $104.1M | $49.3M | ||
| Q2 24 | $-29.0M | $42.2M | ||
| Q1 24 | $182.0M | $44.7M |
自由现金流HCIRGEN
| Q4 25 | $440.8M | $17.6M | ||
| Q3 25 | $25.9M | $43.4M | ||
| Q2 25 | $144.5M | $21.5M | ||
| Q1 25 | $160.3M | $11.4M | ||
| Q4 24 | $327.8M | $33.6M | ||
| Q3 24 | $103.2M | $42.3M | ||
| Q2 24 | $-30.1M | $37.4M | ||
| Q1 24 | $181.0M | $36.4M |
自由现金流率HCIRGEN
| Q4 25 | 179.0% | 8.9% | ||
| Q3 25 | 12.0% | 23.0% | ||
| Q2 25 | 65.1% | 11.8% | ||
| Q1 25 | 74.1% | 6.8% | ||
| Q4 24 | 202.5% | 19.3% | ||
| Q3 24 | 58.9% | 27.3% | ||
| Q2 24 | -14.6% | 24.3% | ||
| Q1 24 | 87.6% | 24.0% |
资本支出强度HCIRGEN
| Q4 25 | 1.5% | 4.1% | ||
| Q3 25 | 0.4% | 2.5% | ||
| Q2 25 | 0.2% | 3.9% | ||
| Q1 25 | 0.8% | 2.1% | ||
| Q4 24 | 2.5% | 3.2% | ||
| Q3 24 | 0.5% | 4.5% | ||
| Q2 24 | 0.5% | 3.1% | ||
| Q1 24 | 0.5% | 5.5% |
现金转化率HCIRGEN
| Q4 25 | 4.55× | 1.93× | ||
| Q3 25 | 0.41× | 3.23× | ||
| Q2 25 | 2.19× | 1.92× | ||
| Q1 25 | 2.32× | 2.57× | ||
| Q4 24 | 128.41× | — | ||
| Q3 24 | 18.33× | — | ||
| Q2 24 | -0.54× | 12.70× | ||
| Q1 24 | 3.82× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
RGEN
暂无分部数据
